SI0801564T1 - Use of nebivolol as an anti-atherogenic - Google Patents

Use of nebivolol as an anti-atherogenic

Info

Publication number
SI0801564T1
SI0801564T1 SI9530591T SI9530591T SI0801564T1 SI 0801564 T1 SI0801564 T1 SI 0801564T1 SI 9530591 T SI9530591 T SI 9530591T SI 9530591 T SI9530591 T SI 9530591T SI 0801564 T1 SI0801564 T1 SI 0801564T1
Authority
SI
Slovenia
Prior art keywords
alpha
nebivolol
atherogenic
chromanmethanol
iminobis
Prior art date
Application number
SI9530591T
Other languages
English (en)
Slovenian (sl)
Inventor
Chaffoy De Courcelles Didier R.G.G. De
Anne Simone Josephine Lesage
Josepha Eduarda Maria Francisca Leysen
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of SI0801564T1 publication Critical patent/SI0801564T1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
SI9530591T 1994-12-28 1995-12-21 Use of nebivolol as an anti-atherogenic SI0801564T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94203775 1994-12-28
PCT/EP1995/005174 WO1996019987A1 (en) 1994-12-28 1995-12-21 Use of nebivolol as an anti-atherogenic
EP95942209A EP0801564B1 (en) 1994-12-28 1995-12-21 Use of nebivolol as an anti-atherogenic

Publications (1)

Publication Number Publication Date
SI0801564T1 true SI0801564T1 (en) 2002-08-31

Family

ID=8217503

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9530591T SI0801564T1 (en) 1994-12-28 1995-12-21 Use of nebivolol as an anti-atherogenic

Country Status (20)

Country Link
US (2) US5874461A (hu)
EP (1) EP0801564B1 (hu)
JP (1) JPH10511655A (hu)
KR (1) KR100264348B1 (hu)
CN (1) CN1167418C (hu)
AT (1) ATE214924T1 (hu)
AU (1) AU700364B2 (hu)
CA (1) CA2207333C (hu)
CZ (1) CZ287513B6 (hu)
DE (1) DE69526120T2 (hu)
DK (1) DK0801564T3 (hu)
ES (1) ES2176354T3 (hu)
FI (1) FI118884B (hu)
HU (1) HU226208B1 (hu)
NO (1) NO315687B1 (hu)
NZ (1) NZ298074A (hu)
PT (1) PT801564E (hu)
SI (1) SI0801564T1 (hu)
SK (1) SK282144B6 (hu)
WO (1) WO1996019987A1 (hu)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100264348B1 (ko) * 1994-12-28 2000-08-16 디르크 반테 항-죽종형성제로서 네비볼롤을 함유하는 조성물
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
JP2000207219A (ja) * 1999-01-18 2000-07-28 Fujitsu Ten Ltd 車載端末とセンタ―との間の通信システム、及び、通信システムに使用する車載端末
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
EP1406608B1 (en) 2001-05-02 2009-07-29 Nitromed, Inc. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
JP4599292B2 (ja) * 2002-10-30 2010-12-15 エジソン ファーマシューティカルズ, インコーポレイテッド 物理的−化学的特性に基づく治療用化合物の同定
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
CA2580584C (en) * 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
EP1741712B1 (en) 2004-07-30 2011-06-15 Torrent Pharmaceuticals Ltd amorphous form of nebivolol hydrochloride and its preparation
EP1848424B1 (en) * 2005-01-31 2017-04-05 Mylan Laboratories, Inc Pharmaceutical composition comprising hydroxylated nebivolol
ES2714900T3 (es) 2005-06-01 2019-05-30 Bioelectron Tech Corp Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ, インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
EP3456707B1 (en) 2007-11-06 2020-04-15 PTC Therapeutics, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
JP5710277B2 (ja) 2008-03-05 2015-04-30 エジソン ファーマシューティカルズ, インコーポレイテッド 酸化ストレス疾患の処置のための2−置換−p−キノン誘導体
US8314153B2 (en) 2008-09-10 2012-11-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
AU2009327411A1 (en) * 2008-12-19 2010-06-24 Merck Sharp & Dohme Corp. Feed supplement for mammalian cell culture and methods of use
HUE037574T2 (hu) 2009-04-28 2018-09-28 Bioelectron Tech Corp Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal
US20130065910A1 (en) * 2010-06-04 2013-03-14 Comprehensive Drug Enterprises Ltd. Oral meclizine aqueous formulations with taste flavoring agent
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
DE102014107132A1 (de) 2014-05-20 2015-11-26 Corden Pharma International Gmbh Verfahren zur Herstellung von Epoxiden die in der Herstellung von Nebivolol und dessen Derivaten einsetzbar sind
AU2015335391B2 (en) * 2014-10-24 2018-06-21 Launx Biomedical Co., Ltd. Uses of duloxetine HCL medicament in preparing pharmaceutical composition for treatment of cancer
RU2770091C2 (ru) 2014-12-16 2022-04-14 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Полиморфные и аморфные формы (r)-2-гидрокси-2-метил-4-(2,4,5-триметил-3,6-диоксоциклогекса-1,4-диенил)бутанамида
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1337432C (en) * 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
KR100264348B1 (ko) * 1994-12-28 2000-08-16 디르크 반테 항-죽종형성제로서 네비볼롤을 함유하는 조성물

Also Published As

Publication number Publication date
KR100264348B1 (ko) 2000-08-16
CN1167418C (zh) 2004-09-22
CZ191997A3 (cs) 1999-01-13
EP0801564A1 (en) 1997-10-22
HUT77927A (hu) 1998-11-30
CZ287513B6 (en) 2000-12-13
NO315687B1 (no) 2003-10-13
DK0801564T3 (da) 2002-07-15
AU4347796A (en) 1996-07-19
NO972980L (no) 1997-06-26
NZ298074A (en) 2001-01-26
SK85697A3 (en) 2000-04-10
DE69526120D1 (de) 2002-05-02
PT801564E (pt) 2002-09-30
US6075046A (en) 2000-06-13
MX9704669A (es) 1997-09-30
CA2207333C (en) 2006-10-17
CN1171739A (zh) 1998-01-28
HU226208B1 (en) 2008-06-30
US5874461A (en) 1999-02-23
CA2207333A1 (en) 1996-07-04
FI972793A (fi) 1997-06-27
JPH10511655A (ja) 1998-11-10
ES2176354T3 (es) 2002-12-01
SK282144B6 (sk) 2001-11-06
FI972793A0 (fi) 1997-06-27
EP0801564B1 (en) 2002-03-27
NO972980D0 (no) 1997-06-26
FI118884B (fi) 2008-04-30
WO1996019987A1 (en) 1996-07-04
DE69526120T2 (de) 2002-11-28
ATE214924T1 (de) 2002-04-15
AU700364B2 (en) 1999-01-07

Similar Documents

Publication Publication Date Title
SI0801564T1 (en) Use of nebivolol as an anti-atherogenic
CA2272584A1 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
BG107537A (en) Method for the inhibition of human tnf alpha activity and its application
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
EP0923376A4 (en) TREATMENT OF ASTHMA AND RESPIRATORY DISEASES
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
ATE252897T1 (de) Verwendung von p-aminophenolderivaten zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von neurodegenerativen erkrankungen
ATE231849T1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
BG105275A (en) Tan-1057 derivatives
BG102667A (en) Diosgenine-containing composition
BG102707A (en) New triazolopurinpurines, method for their preparation and appplication as medicamentous forms
IL143382A0 (en) Human adult astrocytes, their preparation and uses thereof
MD970254A (en) Use of melatonine for treatment of patients having a medicamental dependence
AU1278600A (en) Novel therapeutic application of nicergoline
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
AU2392797A (en) Use of benzonaphthalene derivatives for the manufacture of medicaments for the treatment of diseases of the nervous system
WO1996025931A3 (en) Use of fused benzothiazoles as neuroprotectants
AU1569700A (en) Novel therapeutic application of low molecular weight heparin
HUP0004647A2 (hu) Glükóz-amino-glükánok alkalmazása diabétesszel társult szembetegségek kezelésére szolgáló gyógyszerkészítmények előállítására
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
MX9706931A (es) Derivados de amida de acido-2-ciano-3,5-dihidroxi-hex-2-eno-carboxilico.
BG102864A (en) Application of phosphonic acid esters for the treatment of functional disorders of the brain and depressions